Staunch Opposition to Animal Testing to drive the In-Vitro Toxicology Testing Market

Date : Feb 04, 2021 Author : PMR Editorial Staff Category : Healthcare

In-Vitro toxicity testing, as the name suggests, does study the toxic chemical substances’ impact on the micro-tissues or cultured cells. In other words, it is primarily used for identifying the chemicals that prove to be potentially hazardous at the early stages of agrichemicals or new pharmaceuticals being developed. Animal testing is facing oppositions from across the globe. This factor is basically driving the demand for in-Vitro toxicity testing.

In-Vitro toxicity testing, as the name suggests, does study the toxic chemical substances’ impact on the micro-tissues or cultured cells. In other words, it is primarily used for identifying the chemicals that prove to be potentially hazardous at the early stages of agrichemicals or new pharmaceuticals being developed. Animal testing is facing oppositions from across the globe. This factor is basically driving the demand for in-Vitro toxicity testing.

Also, quicker testing is being asked for. As such, the US FDA has gone ahead with approval of several in-Vitro diagnostic kits like PCR testing panels and in-Vitro diagnostic assays along with drugs that could be used in emergency (like the recent outbreak of Covid-19).

Initially, when animal testing was being carried out, safety risks and high costs were involved. Also, the possibility of zoonotic diseases with rabbit and rodent models being into picture couldn’t be ruled out. The European Union did take stringent steps in this regard. Since 2004, The EU has prohibited testing on the part of various finished cosmetic products on the animals. Moreover, since the year 2009, the same EU imposed a ban on testing of cosmetic ingredients on the animals.

At the same time, several countries across the other parts of the world have been reluctant on the count of making use of in-Vitro testing due to lack of awareness herein. Also, as per Tufts Center for the Study of Drug Development, the last few years have witnessed a visible decline in productivity of the pharmaceutical industry as development costs have been increasing. Herein, personalized medicine by using the in-Vitro methods is witnessing an exponential increase in demand.

However, it needs to be noted that the labour-intensive techniques for performing experiments along with skilled professionals like technicians and researchers are required for setting up and running tests and experiments, making observations, obtaining results, and analysing data. The healthcare industry is facing a dearth of these skilled professionals. The lack of knowledge with respect to choosing the apt technique of in-Vitro testing is likely to result in loads of indirect expenses, which could end up in increasing workload as well as time pressure on the service providers and researchers.

The period between 2020 and 2030 is likely to see a sea change in revenue generation pertaining to toxicity endpoints and tests, which are inclusive of skin irritation, ADME, sensitization, corrosion, cytotoxicity, genotoxicity, organ toxicity, ocular toxicity, dermal toxicity, phototoxicity.

PersistenceMarketResearch, through its latest report entitled “In-Vitro Toxicology Testing Market”, profiles the key players that include Covance, Charles River Laboratories International, Inc., Cyprotex, QIAGEN N.V., MB Research Laboratories, Eurofins Scientific SE, GE Healthcare, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Promega Corporation, BioIVT, Gentronix Ltd., and Merck KGaA.

PersistenceMarketResearch has also unleashed the organic developments. For instance – Covance, in Aug 2019, did launch a laboratory solution with FSPx (functional service provider) offering. It consists of clinical operations capabilities and clinical analytics services[1]. Also, Eurofins, in May 2018, did open a new-fangled food testing laboratory in Suzhou with an investment of EUR 3 Mn for expanding presence all over the Asia-Pacific[2].

PersistenceMarketResearch has also entailed the market region-wise. Out of North America, LATAM, Europe, the Asia-Pacific, and MEA, the Asia-Pacific is expected to witness the highest CAGR between 2020 and 2030. The increasing pipeline of pharmaceutical drugs could be credited to this growth. It also states that North America and Europe are already at the forefront herein.

Reference Links:

  1. https://www.contractpharma.com/contents/view_breaking-news/2019-08-29/covance-launches-lab-solution-within-fspx-offering/
  2. http://www.fnbnews.com/Top-News/eurofins-inaugurates-newlyupgraded-food-testing-laboratory-in-suzhou-43251